Hormone cocktail aims to stop rare salivary cancer recurrence
NCT ID NCT06348264
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing whether a combination of rezvilutamide (a hormone-blocking pill) and standard hormone therapy can prevent high-risk salivary duct cancer from returning after surgery and radiation. About 37 participants with androgen receptor-positive cancer will receive the treatment for up to 2 years. The main goal is to see how many remain cancer-free after 3 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rezvilutamide (a hormone-blocking drug) plus leuprolide acetate (a hormone therapy)
- What this could lead to
- If successful, this combination could offer a new way to lower the risk of cancer returning in people with high-risk salivary duct cancer.
- What could go wrong
- This is a small, early-phase trial with only 37 participants and no comparison group, so results may not be definitive. Hormone therapy can cause side effects like hot flashes, fatigue, and sexual changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVARY GLAND NEOPLASM DUCT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China
-
Peking University School and Hospital of Stomatology
RECRUITINGBeijing, Beijing Municipality, China